Carvedilol Tablet, Film Coated
Product Images NDC 71335-2023

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 71335-2023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Tab Usp Figure1)

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Tab Usp Figure1)
A line chart showing percent mortality over 24 months comparing Carvedilol and placebo groups. The graph charts mortality rates, with Carvedilol showing consistently lower mortality percentages than placebo, indicating a difference in survival over time.*
FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Tab Usp Figure2)

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Tab Usp Figure2)
A forest plot depicting hazard ratios across various subgroups including gender (men, women), age groups (<65, ≥65), race (non-black, black), diabetic status, ischemic condition, heart rate, systolic blood pressure categories, and spironolactone use, with all patients combined at the bottom. The plot displays hazard ratios with confidence intervals, relative to a baseline of 1.0.*
FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Tab Usp Figure3)

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Tab Usp Figure3)
A Kaplan-Meier curve chart showing cumulative mortality percentage over 30 months for two groups labeled Carvedilol and Placebo. The graph has mortality percentage on the y-axis and months on the x-axis, illustrating a comparison of survival between the two groups with a P-value of 0.03 indicated on the chart.*
FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Tab Usp Figure4)

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Tab Usp Figure4)
A forest plot displaying hazard ratios for various patient subgroups, including age, gender, prior medication use, clinical classifications, and comorbidities such as diabetes and hypertension. The plot compares outcomes within each subgroup, showing point estimates with confidence intervals centered around a hazard ratio of 1.0, indicating relative risks in different clinical contexts.*
FDA Label Image

Carvedilol Chemical Structure (Carvedilol Tab Usp Structure)

Carvedilol Chemical Structure (Carvedilol Tab Usp Structure)
Chemical structure of carvedilol, showing the molecular arrangement with connected rings and side chains including a methoxyphenyl group and ethanolamine moiety.*
FDA Label Image

Label (Lbl713352023)

Label (Lbl713352023)
Carvedilol 25 mg tablet label from Bryant Ranch Prepack. The label includes storage instructions to keep at 20°-25°C (68°-77°F) and a safety warning to keep all drugs out of reach of children. The label references a comparison to Coreg 25 mg tablets, indicates Rx only, and displays a lot number and NDC 71335-20231.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.